Ian E. Krop
Impact in
- Oncology top 0.05%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Research top 0.1%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 131
- HER2/EGFR in Cancer Research 118
- Cancer Immunotherapy and Biomarkers 6
-
- Breast Cancer Treatment Studies 38
- Cancer Genomics and Diagnostics 6
- Co-authors
- Eric P. Winer (73 shared papers)Veronique C Dieras (10 shared papers)Manfred Welslau (3 shared papers)David W. Miles (4 shared papers)José Baselga (8 shared papers)Ellie Guardino (5 shared papers)Mark Daniel Pegram (5 shared papers)Sunil Verma (5 shared papers)
- Journals
- Annals of Oncology (47 papers)Journal of Clinical Oncology (42 papers)Clinical Cancer Research (21 papers)Breast Cancer Research and Treatment (15 papers)ESMO Open (13 papers)
- Partner nations
- United StatesSpainFrance
In The Last Decade
Ian E. Krop
282 papers receiving 33.0k citations
Ian E. Krop's Hit Papers
Peers
Comparison fields: 5 of 100
- Oncology 10.1k
- Cancer Research 4.7k
- Pulmonary and Respiratory Medicine 4.6k
- Radiology, Nuclear Medicine and Imaging 1.7k
- Biomaterials 648
Countries citing papers authored by Ian E. Krop
This map shows the geographic impact of Ian E. Krop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ian E. Krop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ian E. Krop more than expected).
Fields of papers citing papers by Ian E. Krop
This network shows the impact of papers produced by Ian E. Krop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ian E. Krop. The network helps show where Ian E. Krop may publish in the future.
Co-authors
The 25 scholars most cited alongside Ian E. Krop, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 294 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer Hit paper breakdown → | 2012 | 3096 |
| 2 | 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) Hit paper breakdown → | 2016 | 1808 |
| 3 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer Hit paper breakdown → | 2019 | 1606 |
| 4 | CDK4/6 inhibition triggers anti-tumour immunity Hit paper breakdown → | 2017 | 1187 |
| 5 | Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer Hit paper breakdown → | 2019 | 992 |
| 6 | 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) Hit paper breakdown → | 2018 | 884 |
| 7 | Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens Hit paper breakdown → | 2017 | 876 |
| 8 | Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy Hit paper breakdown → | 2010 | 638 |
| 9 | Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study Hit paper breakdown → | 2020 | 633 |
| 10 | Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2014 | 590 |
| 11 | 2015 | 561 | |
| 12 | 2017 | 541 | |
| 13 | 2016 | 538 | |
| 14 | 2010 | 492 | |
| 15 | 2014 | 466 | |
| 16 | 2017 | 439 | |
| 17 | Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors Hit paper breakdown → | 2016 | 382 |
| 18 | 2020 | 372 | |
| 19 | 2015 | 338 | |
| 20 | 2014 | 334 |
About Ian E. Krop
Ian E. Krop is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Molecular Biology and Genetics, having authored 294 papers that have together received 33.8k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (118 papers), Breast Cancer Treatment Studies (38 papers), Advanced Breast Cancer Therapies (20 papers), Brain Metastases and Treatment (18 papers), PI3K/AKT/mTOR signaling in cancer (10 papers), Cancer Immunotherapy and Biomarkers (6 papers), Cancer Genomics and Diagnostics (6 papers) and Reproductive Biology and Fertility (3 papers). The work is most often cited by research in Oncology (10.1k citations), Cancer Research (4.7k citations), Pulmonary and Respiratory Medicine (4.6k citations), Radiology, Nuclear Medicine and Imaging (1.7k citations) and Biomaterials (648 citations). Ian E. Krop has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Eric P. Winer, Veronique C Dieras, Manfred Welslau, David W. Miles, José Baselga, Ellie Guardino, Mark Daniel Pegram, Sunil Verma, Luca Gianni and Sara Tolaney. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Clinical Cancer Research, Breast Cancer Research and Treatment and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.